Case Control Study
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jun 14, 2023; 29(22): 3482-3496
Published online Jun 14, 2023. doi: 10.3748/wjg.v29.i22.3482
Plasma exosomal hsa_circ_0079439 as a novel biomarker for early detection of gastric cancer
Xiao Li, Yan-Li Lin, Jia-Kang Shao, Xiao-Jie Wu, Xiang Li, He Yao, Fa-Liang Shi, Long-Song Li, Wen-Gang Zhang, Zheng-Yao Chang, Ning-Li Chai, You-Liang Wang, En-Qiang Linghu
Xiao Li, Long-Song Li, Wen-Gang Zhang, Ning-Li Chai, En-Qiang Linghu, Department of Gastroenterology, The First Medical Center of Chinese PLA General Hospital, Beijing 100853, China
Xiao Li, Jia-Kang Shao, Long-Song Li, Wen-Gang Zhang, Zheng-Yao Chang, Medical School of Chinese PLA, Beijing 100853, China
Xiao Li, Yan-Li Lin, Xiao-Jie Wu, Xiang Li, He Yao, Fa-Liang Shi, You-Liang Wang, Beijing Institute of Biotechnology, Beijing 100071, China
Author contributions: Chai NL, Wang YL, and Linghu EQ designed the study; Li X, Shao JK, Li LS, Zhang WG, and Chang ZY collected the plasma samples; Li X, Lin YL, Wu XJ, Yao H, Shi FL, and Li X performed the dd-PCR test and data analysis; Li X, Lin YL, and Shao JK contributed equally to this work, and they should be considered as co-first authors; Chai NL, Wang YL, and Linghu EQ were co-corresponding authors; and all authors approved the final manuscript.
Supported by the National Key Research and Development Program, No. 2019YFA0903802, 2022YFC2503600, and 2016YFC1303601.
Institutional review board statement: This study was approved by the ethics committee of Chinese PLA General Hospital.
Informed consent statement: Informed consent was obtained from all participants in this study.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: The data that support the findings of this study are available from the corresponding author upon reasonable request.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: En-Qiang Linghu, PhD, Chief Physician, Professor, Department of Gastroenterology, The First Medical Center of Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing 100853, China. linghuenqiang@vip.sina.com
Received: April 16, 2023
Peer-review started: April 16, 2023
First decision: April 28, 2023
Revised: May 4, 2023
Accepted: May 11, 2023
Article in press: May 11, 2023
Published online: June 14, 2023
Processing time: 51 Days and 11.8 Hours
Core Tip

Core Tip: Gastric cancer (GC) remains a prevalent disease worldwide. Due to its atypical clinical manifestations, GC is usually diagnosed at late stages in most patients and has a poor prognosis. Therefore, early detection of GC is of great importance. Based on the results of exosomal whole-transcriptome RNA sequencing, we performed bioinformatic analysis and droplet digital polymerase chain reaction (dd-PCR) tests. As validated by dd-PCR, exosomal hsa_circ_0079439 had a higher area under the curve value than standard biomarkers. Therefore, plasma exosomal hsa_circ_0079439 could serve as a novel biomarker for the early detection of GC.